



Medication Trend Updates and Formulary Changes – 2nd Quarter 2018

This update includes information regarding alternative sites of infusion care for commercial members, patent expiration, HIV pre-exposure prophylaxis and post-exposure prevention, availability of osteoporosis outreach reports, and changes to the Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company (Health Net) commercial *Recommended Drug Lists (RDLs)*, *Medi-Cal RDL* and *Medicare Part D Formularies* for the second quarter of 2018.

ALTERNATIVE SITES FOR INFUSION CARE FOR COMMERCIAL MEMBERS

Health Net continually looks for ways to help our members better manage and obtain medication therapies. Patients who are being treated with immunoglobulin or Remicade® have the option to transition infusions from the hospital to the home or an ambulatory infusion suite (AIS) for optimal comfort and convenience. The option for alternate site of infusion care is already built into members' standard benefits. Health Net has partnered with Coram® CVS Specialty™ Infusion Services as our designated provider for these infusions. Coram has more than 30 years of experience providing specialized infusion care and has demonstrated expertise in the delivery and administration of complex specialty infused medications.

Alternate infusion care sites are safe, increase patient comfort and convenience and may lower health costs.

- **Safety** – Clinicians are certified and specialize in delivery of chronic and complex drug therapy, and careful patient monitoring. Experienced nurses stay for the entire infusion duration, ensuring patients receive high-level care.
- **Convenience** – In-home and AIS-based infusions are scheduled directly with patients, enabling flexibility, independence and enhanced quality of life. Clinical support is available to patients 24 hours a day, 7 days a week.
- **Cost effectiveness** – Infusions may be provided at a lower cost to patients, promoting compliance to therapy, and ultimately improving outcomes and reducing health costs.

For patient referrals or additional information, please call Peter Tran, PharmD, at (714) 934-3362 Monday through Friday from 9:00 a.m. to 4:00 p.m. and reference the Site of Care Optimization of Therapeutic Infusion (SCOTI) Program.

PATENT EXPIRATION FOR COMMONLY USED BRAND-NAME MEDICATIONS

Patents are granted by the United States Patent and Trademark Office along the development lifeline of a medication. Patents expire 20 years from the date of filing. Many factors can affect the duration of a patent. When a brand-name medication loses its patent, lower-priced generics enter the market. U.S. Food and Drug Administration (FDA)-approved generic drugs are made under the same rigorous standards as their brand-name counterparts and are bioequivalent, delivering the same amount of active ingredients into a patient's bloodstream in the same amount of time as their brand-name product. During the upcoming year, the key medications listed below are anticipated to be available as generic equivalents.

THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

LINES OF BUSINESS:

- HMO/POS/HSP
- PPO
- EPO
- Medicare Advantage (HMO)
- Medi-Cal
 - Kern
 - Los Angeles
 - Molina
 - Riverside
 - Sacramento
 - San Bernardino
 - San Diego
 - San Joaquin
 - Stanislaus
 - Tulare

PROVIDER SERVICES

provider_services@healthnet.com

EnhancedCare PPO (IFP)

1-844-463-8188

provider.healthnetcalifornia.com

EnhancedCare PPO (SBG)

1-844-463-8188

provider.healthnet.com

Health Net Employer Group HMO, POS, HSP, PPO, & EPO

1-800-641-7761

provider.healthnet.com

IFP – CommunityCare HMO, PPO, PureCare HSP, PureCare One EPO

1-888-926-2164

provider.healthnetcalifornia.com

Medicare (Individual)

1-800-929-9224

provider.healthnetcalifornia.com

Medicare (employer group)

1-800-929-9224

provider.healthnet.com

Medi-Cal – 1-800-675-6110

provider.healthnet.com

PROVIDER COMMUNICATIONS

provider.communications@

healthnet.com

fax 1-800-937-6086

Medication Patent Expirations

	2018	2019
1ST QUARTER	Solodyn [®] (65 mg, 115 mg) [^]	Latuda, [®] [^] Ranexa [®]
2ND QUARTER	Adcirca, [®] NuvaRing, [®] Remodulin [®]	Levitra, [®] Lyrica, [®] Travatan Z, [®] Vesicare [®]
3RD QUARTER	Acanya, [®] [^] Sensipar [®]	Gilenya [®]
4TH QUARTER	Canasa, [®] Cialis, [®] Rapaflo [®]	Exjade [®] [^]

[^] Nonformulary

HIV PRE-EXPOSURE PROPHYLAXIS AND POST-EXPOSURE PREVENTION FOR MEDI-CAL MEMBERS

A recent notification from the Department of Health Care Services (DHCS) to health plans details issues regarding treatment delay and denials of pre-exposure prophylaxis (PrEP) and post-exposure prevention (PEP) medications used to prevent seroconversion to HIV. This has the potential to negatively impact beneficiaries, as the consequences of delaying or denying access to these medications can be life-altering.

DHCS would like managed care organizations (MCOs) to remind and educate their respective network providers, network pharmacies and staff about the scope of benefit and the proper submission of claims for these medications. These medications are considered a non-capitated, covered benefit and are billed through the Medi-Cal fee-for-service (FFS) system and not through the MCOs.

For all inquiries regarding HIV pre- or post-exposure prophylaxis, participating physician groups (PPGs) should advise that a Treatment Authorization Request (TAR) is not required by DHCS and should not delay treatment and/or prophylaxis.

Please share this information with any providers, pharmacies or staff that provide care for members that may be affected by this issue so that time-sensitive treatment is not delayed.

Additional information and resources for consumers and providers regarding PrEP and PEP are available at: www.cdc.gov/hiv/risk/index.html.

OSTEOPOROSIS MEMBER OUTREACH REPORTS AVAILABLE

Healthcare Effectiveness Data and Information Set (HEDIS[®]) reports with results from the most current and complete reporting cycle for members with osteoporosis participating in the Management of Post-Menopausal Women with Osteoporotic Fractures Program are now available to providers. This program is a health education outreach and intervention for Health Net Medicare Advantage (MA) members ages 65 to 85 who have had an osteoporotic fracture in the past three months and have not received a bone-mineral density (BMD) test or are not currently taking prescription medication.

PPGs can access reports with specific HEDIS results to identify areas for improvement or best practices. The report provides monthly gap lists for specific measures to identify gaps in data and drive member gap closure. These reports are available on the Health Net provider portal, as listed in the table below. If technical assistance is needed to gain access to these reports, please contact Health Net's Web Support at 1-866-458-1047.

CHANGES TO THE RECOMMENDED DRUG LIST AND MEDICARE PART D FORMULARIES

The Health Net Pharmacy and Therapeutics (P&T) Committee, which comprises practicing physicians, pharmacists and other health care professionals, reviews medications on the Health Net *Recommended Drug Lists (RDLs)* and *Formularies* for commercial and Medi-Cal members, and the *Medicare Part D Formularies* for Medicare members each quarter to determine medications to remain on or be moved to a different tier. A list of some recent changes is provided beginning on page 4. The list contains brand-name prescription medications, status, alternatives, and comments for the second quarter of 2018.

Complete lists of the *RDLs*, *Formularies* and *Medicare Part D Formularies* are available on the Health Net provider portal, as listed in the table below, by selecting *Pharmacy Information* or *Provider Library*. Other pharmacy-related provider updates, prior authorization criteria and pharmacy forms are also available online under *Pharmacy Information*.

PHARMACY HELP LINE

For additional information regarding changes to the commercial Health Net *RDL*, Health Net Medi-Cal *RDLs* or *Medicare Part D Formularies*, contact the appropriate pharmacy telephone numbers listed below:

- **Pharmacy Services** (commercial): 1-800-548-5524, option #3; fax 1-800-314-6223
- **Pharmacy Service Center** (Medi-Cal and Medicare): 1-800-867-6564; fax 1-800-977-8226
- **Health Net Clinical Pharmacy Line** (clinical programs): 1-800-782-2221

ADDITIONAL INFORMATION

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center within 60 days at:

Line of Business	Telephone Number	Provider Portal	Email Address
ENHANCEDCARE PPO (IFP)	1-844-463-8188	provider.healthnetcalifornia.com	provider_services@healthnet.com
ENHANCEDCARE PPO (SBG)	1-844-463-8188	provider.healthnet.com	
HEALTH NET EMPLOYER GROUP HMO, POS, HSP, PPO, & EPO	1-800-641-7761	provider.healthnet.com	
IFP (COMMUNITYCARE HMO, PPO, PURECARE HSP, PURECARE ONE EPO)	1-888-926-2164	provider.healthnetcalifornia.com	
MEDICARE (INDIVIDUAL)	1-800-929-9224	provider.healthnetcalifornia.com	
MEDICARE (EMPLOYER GROUP)	1-800-929-9224	provider.healthnet.com	
MEDI-CAL	1-800-675-6110	provider.healthnet.com	N/A

HEALTH NET RECOMMENDED DRUG LIST (RDL), MEDI-CAL FORMULARY AND MEDICARE PART D FORMULARY CHANGES

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial 3-Tier Plan (4-Tier Plan)	Medicare Part D Value ¹	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value ¹ (Tier 1, 2, 3, or 6)	Medi-Cal	
ORAL MEDICATIONS							
Baxdela® (delafloxacin) tablet	NF (NF)	Tier 5 (EST)	NF	ciprofloxacin, levofloxacin, moxifloxacin	ciprofloxacin, levofloxacin	ciprofloxacin, levofloxacin	<p>Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following:</p> <p>Gram-positive organisms: <i>Staphylococcus aureus</i> (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), <i>Staphylococcus haemolyticus</i>, <i>Staphylococcus lugdunensis</i>, <i>Streptococcus agalactiae</i>, <i>Streptococcus anginosus</i> group (including <i>Streptococcus anginosus</i>, <i>Streptococcus intermedius</i>, and <i>Streptococcus constellatus</i>), <i>Streptococcus pyogenes</i>, and <i>Enterococcus faecalis</i></p> <p>Gram-negative organisms: <i>Escherichia coli</i>, <i>Enterobacter cloacae</i>, <i>Klebsiella pneumoniae</i>, and <i>Pseudomonas aeruginosa</i></p> <p>Electronic step therapy requires a trial of one fluoroquinolone.</p>

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial 3-Tier Plan (4-Tier Plan)	Medicare Part D Value ¹	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value ¹ (Tier 1, 2, 3, or 6)	Medi-Cal	

ORAL MEDICATIONS, CONTINUED

Odactra™ House Dust Mite (<i>Dermatophagoides farinae</i> and <i>Dermatophagoides pteronyssinus</i>) Allergen Extract sublingual tablet	NF (NF)	Medicare excluded	NF	Intranasal steroids: fluticasone (Flonase®), mometasone (Nasonex®) Nasal antihistamines: azelastine (Astelin®) Leukotriene inhibitor: montelukast (Singulair®)	Oral antihistamines: desloratadine (Clarinex®) Intranasal steroids: fluticasone (Flonase), triamcinolone (Nasacort® AQ), mometasone (Nasonex) Nasal antihistamines: azelastine (Astelin) Leukotriene inhibitor: montelukast (Singulair), zileuton (Zyflo CR®)	Oral antihistamines: loratadine (Claritin®), cetirizine (Zyrtec®) Intranasal steroids: fluticasone (Flonase) Nasal antihistamines: azelastine (Astelin) Leukotriene inhibitor: montelukast (Singulair)	Indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for immunoglobulin E (IgE) antibodies to <i>Dermatophagoides farinae</i> or <i>Dermatophagoides pteronyssinus</i> house dust mites or skin testing to licensed house dust mite allergen extracts in adults ages 18 through 65
---	---------	-------------------	----	--	--	---	---

¹Medicare Part D Value Formulary = Health Net Seniority Plus Amber I (HMO SNP), Health Net Seniority Plus Amber II (HMO SNP), Health Net Healthy Heart (HMO)

- EST indicates step therapy required
- F indicates formulary
- NF indicates nonformulary. Medications require member-specific medical reasons why formulary medications cannot be considered. Requests are reviewed via Health Net's prior authorization process.

PROVIDER Update



Health Net®

CONTRACTUAL | MAY 2, 2018 | UPDATE 18-290sum | 3 PAGES

Summary Update: Medication Trend Updates and Formulary Changes – 2nd Quarter 2018

This update includes information regarding alternative sites of infusion care for commercial members, patent expiration, HIV pre-exposure prophylaxis and post-exposure prevention, availability of osteoporosis outreach reports, and changes to the Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company (Health Net) commercial *Recommended Drug Lists (RDLs)*, *Medi-Cal RDL* and *Medicare Part D Formularies* for the second quarter of 2018.

ALTERNATIVE SITES FOR INFUSION CARE FOR COMMERCIAL MEMBERS

Health Net continually looks for ways to help our members better manage and obtain medication therapies. Patients who are being treated with immunoglobulin or Remicade® have the option to transition infusions from the hospital to the home or an ambulatory infusion suite (AIS) for optimal comfort and convenience. The option for alternate site of infusion care is already built into members' standard benefits. Health Net has partnered with Coram® CVS Specialty™ Infusion Services as our designated provider for these infusions. Coram has more than 30 years of experience providing specialized infusion care and has demonstrated expertise in the delivery and administration of complex specialty infused medications.

Alternate infusion care sites are safe, increase patient comfort and convenience and may lower health costs.

- Safety – Clinicians are certified and specialize in delivery of chronic and complex drug therapy, and careful patient monitoring. Experienced nurses stay for the entire infusion duration, ensuring patients receive high-level care.
- Convenience – In-home and AIS-based infusions are scheduled directly with patients, enabling flexibility, independence and enhanced quality of life. Clinical support is available to patients 24 hours a day, 7 days a week.
- Cost effectiveness – Infusions may be provided at a lower cost to patients, promoting compliance to therapy, and ultimately improving outcomes and reducing health costs.

For patient referrals or additional information, please call Peter Tran, PharmD, at (714) 934-3362 Monday through Friday from 9:00 a.m. to 4:00 p.m. and reference the Site of Care Optimization of Therapeutic Infusion (SCOTI) Program.

PATENT EXPIRATION FOR COMMONLY USED BRAND-NAME MEDICATIONS

Patents are granted by the United States Patent and Trademark Office along the development lifeline of a medication. Patents expire 20 years from the date of filing. Many factors can affect the duration of a patent. When a brand-name medication loses its patent, lower-priced generics enter the market. U.S. Food and Drug Administration (FDA)-approved generic drugs are made under the same rigorous standards as their brand-

THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

LINES OF BUSINESS:

- HMO/POS/HSP
- PPO
- EPO
- Medicare Advantage (HMO)
- Medi-Cal
 - Kern
 - Los Angeles
 - Molina
 - Riverside
 - Sacramento
 - San Bernardino
 - San Diego
 - San Joaquin
 - Stanislaus
 - Tulare

PROVIDER SERVICES

provider_services@healthnet.com

EnhancedCare PPO (IFP)

1-844-463-8188

provider.healthnetcalifornia.com

EnhancedCare PPO (SBG)

1-844-463-8188

provider.healthnet.com

Health Net Employer Group HMO, POS, HSP, PPO, & EPO

1-800-641-7761

provider.healthnet.com

IFP – CommunityCare HMO, PPO, PureCare HSP, PureCare One EPO

1-888-926-2164

provider.healthnetcalifornia.com

Medicare (individual)

1-800-929-9224

provider.healthnetcalifornia.com

Medicare (employer group)

1-800-929-9224

provider.healthnet.com

Medi-Cal – 1-800-675-6110

provider.healthnet.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

healthnet.com

fax 1-800-937-6086

name counterparts and are bioequivalent, delivering the same amount of active ingredients into a patient's bloodstream in the same amount of time as their brand-name product. During the upcoming year, the key medications listed below are anticipated to be available as generic equivalents.

Medication Patent Expirations

	2018	2019
1ST QUARTER	Solodyn [®] (65 mg, 115 mg) [^]	Latuda, [®] [^] Ranexa [®]
2ND QUARTER	Adcirca, [®] NuvaRing, [®] Remodulin [®]	Levitra, [®] Lyrica, [®] Travatan Z, [®] Vesicare [®]
3RD QUARTER	Acanya, [®] [^] Sensipar [®]	Gilenya [®]
4TH QUARTER	Canasa, [®] Cialis, [®] Rapaflo [®]	Exjade [®] [^]

[^] Nonformulary

HIV PRE-EXPOSURE PROPHYLAXIS AND POST-EXPOSURE PREVENTION FOR MEDICAL MEMBERS

A recent notification from the Department of Health Care Services (DHCS) to health plans details issues regarding treatment delay and denials of pre-exposure prophylaxis (PrEP) and post-exposure prevention (PEP) medications used to prevent seroconversion to HIV. This has the potential to negatively impact beneficiaries, as the consequences of delaying or denying access to these medications can be life-altering.

DHCS would like managed care organizations (MCOs) to remind and educate their respective network providers, network pharmacies and staff about the scope of benefit and the proper submission of claims for these medications. These medications are considered a non-capitated, covered benefit and are billed through the Medi-Cal fee-for-service (FFS) system and not through the MCOs.

For all inquiries regarding HIV pre- or post-exposure prophylaxis, participating physician groups (PPGs) should advise that a Treatment Authorization Request (TAR) is not required by DHCS and should not delay treatment and/or prophylaxis.

Please share this information with any providers, pharmacies or staff that provide care for members that may be affected by this issue so that time-sensitive treatment is not delayed.

Additional information and resources for consumers and providers regarding PrEP and PEP are available at: www.cdc.gov/hiv/risk/index.html.

OSTEOPOROSIS MEMBER OUTREACH REPORTS AVAILABLE

Healthcare Effectiveness Data and Information Set (HEDIS[®]) reports with results from the most current and complete reporting cycle for members with osteoporosis participating in the Management of Post-Menopausal Women with Osteoporotic Fractures Program are now available to providers. This program is a health education outreach and intervention for Health Net Medicare Advantage (MA) members ages 65 to 85 who have had an osteoporotic fracture in the past three months and have not received a bone-mineral density (BMD) test or are not currently taking prescription medication.

PPGs can access reports with specific HEDIS results to identify areas for improvement or best practices. The report provides monthly gap lists for specific measures to identify gaps in data and drive member gap closure. These reports are available on the Health Net provider portal, as listed in the table below. If technical assistance is needed to gain access to these reports, please contact Health Net's Web Support at 1-866-458-1047.

CHANGES TO THE RECOMMENDED DRUG LIST AND MEDICARE PART D FORMULARIES

A list of recent changes to the Health Net RDLs and Formularies is available in the complete provider update 18-290, *Medication Trend Updates and Formulary Changes – 2nd Quarter 2018*. The list contains brand-name prescription medications, status, alternatives, and comments. Complete listings of the RDLs and Medicare Part D Formularies are available on the Health Net provider portal, as listed in the table below, by selecting *Pharmacy Information*.

PHARMACY HELP LINE

For additional information regarding changes to the commercial Health Net *RDL*, Health Net Medi-Cal *RDLs* or *Medicare Part D Formularies*, contact the appropriate pharmacy telephone numbers listed below:

- **Pharmacy Services** (commercial): 1-800-548-5524, option #3; fax 1-800-314-6223
- **Pharmacy Service Center** (Medi-Cal and Medicare): 1-800-867-6564; fax 1-800-977-8226
- **Health Net Clinical Pharmacy Line** (clinical programs): 1-800-782-2221

ADDITIONAL INFORMATION

To obtain a comprehensive description of the above topics, the complete update, 18-290, is available on the Health Net provider portal, as listed in the table below, in the Provider Library under *Updates and Letters > 2018*; search for provider update 18-290. Providers who do not have access to the Internet may request a print copy of update 18-290 by contacting the Health Net Provider Communications Department by fax at 1-800-937-6086 or by email at provider.communications@healthnet.com.

For the most current version of the Health Net *RDLs*, visit the Health Net provider portal, as listed in the table below, under *Pharmacy Information > Drug Lists*.

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center within 60 days at:

Line of Business	Telephone Number	Provider Portal	Email Address
ENHANCEDCARE PPO (IFP)	1-844-463-8188	provider.healthnetcalifornia.com	provider_services@healthnet.com
ENHANCEDCARE PPO (SBG)	1-844-463-8188	provider.healthnet.com	
HEALTH NET EMPLOYER GROUP HMO, POS, HSP, PPO, & EPO	1-800-641-7761	provider.healthnet.com	
IFP (COMMUNITYCARE HMO, PPO, PURECARE HSP, PURECARE ONE EPO)	1-888-926-2164	provider.healthnetcalifornia.com	
MEDICARE (INDIVIDUAL)	1-800-929-9224	provider.healthnetcalifornia.com	
MEDICARE (EMPLOYER GROUP)	1-800-929-9224	provider.healthnet.com	
MEDI-CAL	1-800-675-6110	provider.healthnet.com	N/A